Considering that neutralizing low levels of cytokines such as TNF-α in the tumor microenvironment has positive results in cancer treatment, the use of nanobodies to control cytokines and also drug delivery in these environments has an attractive potential for clinical applications [53]. This evidence concerns the gene TNF and cancer.